Cantel Medical — Investor Presentation (December 2012)
22 slides from Cantel Medical's investor presentation, Dec 14, 2012
Slide 1: Infection Prevention & Control Matters
Cantel Medical Corp. (NYSE: CMN) Infection Prevention & Control Matters™ Dec. 2012 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements. All forward-looking statements involve risks and uncertainties, including, without limitation, the risks detailed in the Company’s filin
Slide 2: Cantel Medical Corp. - NYSE Leader in Infection Prevention & Control
2 Cantel Medical Corp. $393M NYSE Leader in Infection Prevention & Control1 Pure-play in a ~$45B Global Infection Prevention & Control Market (“IP&C”) Large, highly fragmented = growth opportunities 18 acquisitions since 2001 have re-shaped the company Have never been better positioned for future gr
Slide 3: Three Synergistic Platforms
3 Cantel Medical Corp. Three Synergistic Platforms Infection Prevention & Control Focus Healthcare & Life Sciences Orientation IP&C Device Management Endoscopy & Renal Dialysis Medivators/Byrne; Minntech Purification & Filtration Water Treatment & Therapeutic Filters Mar Cor Purification; Minntech D
Slide 4: Snapshot: By Product, Customer, Channel
4 Cantel Medical Corp. Snapshot: By Product, Customer, Channel Infection Prevention & Control Focus Healthcare & Life Sciences Orientation Dialysis Equipment, Sterilants, Consumables, Service Endoscopy Equipment, Disinfectants, Consumables, Service Water Purification Equipment, Field Service, Consum
Slide 5: $45 Billion Global Market
5 Cantel Medical Corp. $45 Billion Global Infection Prevention & Control Market Healthcare Associated Infections (HAI’s) are the most common complication of hospital care2 Implementing existing prevention practices yields ~70% reduction in HAIs. Financial benefit ~$25B - $32B in medical cost savings
Slide 6: Healthcare Reform Creates Greater Emphasis in IP&C
6 Cantel Medical Corp. Healthcare Reform Creates Greater Emphasis in IP&C Financial Penalties to Hospitals1 Preventable Readmissions – Estimated $30 billion cost to the system Beginning 2012, Medicare will stop paying hospitals for preventable readmissions tied to heart failure or pneumonia Beginnin
Slide 7: Well-Balanced Portfolio with Emphasis on Endoscopy
7 Cantel Medical Corp. Well-Balanced Portfolio with Emphasis on Endoscopy Latest Twelve Months Ended October 31, 2012 “All Other” includes Therapeutic Filtration Products. Specialty Packaging Products, and Chemistries. 1 Before allocation of corporate expenses of ~$10.9M. 2 Earnings Before Interest,
Slide 8: Significant Upside Growth Opportunities
8 Cantel Medical Corp. Significant Upside Growth Opportunities Acquisitions: 4 recent acquisitions in all three core segments SPSmedical Supply Corp. combined with ConFirm Monitoring creates a leading sterility assurance monitoring platform to drive further growth in acute care, dental and physician
Slide 9: Significant Upside Growth Opportunities
9 Cantel Medical Corp. Significant Upside Growth Opportunities Substantial Sales & Marketing investments in core FY’09-FY’12 Substantial increase in R&D spending in FY’11-FY’12 High-Margin Liquid Chemical Germicides (LCG) New chemistry development capabilities began in FY’11, to yield multiple New P
Slide 10: Byrne Acquisition – Aug 1, 2011
10 Byrne Acquisition – Aug 1, 2011 Endoscopy: Facilitate Accelerated Global Growth Medivators (f/k/a Minntech) subsidiary acquired the assets of Byrne Medical, Inc. for $89.4M in cash and $10.0M in stock, plus $10.0M potential earnout Pre-acquisition revenues of ~$38.6M and EBIT of $10.9M1 Complemen
Slide 11: Medivators Plus Byrne Medical Endoscopy Segment: Complementary Businesses
11 Medivators Plus Byrne Medical Endoscopy Segment: Complementary Businesses Intercept Wipes Veriscan Scope Buddy Intercept CER/DSD/ Advantage Rapicide Rapicide PA IN THE PROCEDURE ROOM Byrne Medical Products Treatment Room Physicians & Nurses Medivators Endoscope Reprocessing Products Principally i
Slide 12: SPSmedical and ConFirm Acquisitions
12 SPSmedical and ConFirm Acquisitions Creates Leading Sterility Assurance Monitoring Platform Crosstex subsidiary acquired SPSmedical Supply Corp. (Nov. 1, 2012) for $32.5M in cash, plus $3.5M for facility. Pre-acquisition revenue of $17.5M Follow on to the prior acquisition of ConFirm Monitoring S
Slide 13: Gambro Acquisition in FY'11
13 Gambro Acquisition in FY’11 Water Treatment Mar Cor Purification subsidiary acquired Gambro’s U.S. water treatment business (Oct 6, 2010) for $23.7M in cash. Pre-acquisition revenues of ~$14.0M. Strategic value akin to success of Mar Cor’s acquisition of GE’s Dialysis Water Business in March 2007
Slide 14: Formula: Acquire, Improve Businesses, Repeat
14 Cantel Medical Corp. Formula: Acquire, Improve Businesses, Repeat CAGR ’03-3M’13 17% 23% * FY’11 Net Debt includes $98M in debt assumed on the first day of fiscal year 2012 upon closing of the Byrne Medical acquisition. †Latest twelve months as of October 31, 2012
Slide 15: Fragmented Nature of Infection Prevention Market
15 Cantel Medical Corp. Fragmented Nature of Infection Prevention & Control Indicates Cantel product offering Key strategic priorities 1 2 3 4 5 Disinfectants & Cleaners Disposables Masks / Headwear Air & Water Quality Protective Apparel Brushes Disposable kits / trays Face shields Air filtration sy
Slide 16: Historical P&L Reveals Success of Acquisition Program
16 Cantel Medical Corp. Historical P&L Reveals Success of Acquisition Program 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Equivalent to “Income from Continuing Operations”. 3 Compound Annual Growth Rate. 4 Latest twelve months as of October 31, 20
Slide 17: Capacity for Continued Investment
17 Cantel Medical Corp. Capacity for Continued Investment 1 Adjusted to include $98 million in debt assumed on 8/1/12 following the acquisition of Byrne Medical. 2 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 3 Retroactively reflects 3:2 stock split ef
Slide 18: Experienced Executive Team – Now organizing for growth
Cantel Medical Corp. Experienced Executive Team – Now organizing for growth Andrew A. Krakauer President & CEO Jorgen B. Hansen Exec. Vice President & Chief Operating Officer Eric W. Nodiff Sr. Vice President General Counsel Craig A. Sheldon Sr. Vice President Chief Financial Officer & Treasurer Set
Slide 19: Strategic Objectives Remain Focused
19 Cantel Medical Corp. Strategic Objectives Remain Focused within Infection Prevention & Control Near-term build a profitable $500 Million Specialty Business. . . setting the strategy for $1 Billion Achieve accelerated growth and profits from the three recent acquisitions Invest in higher technolog
Slide 20: Strategic Evolution
20 Cantel Medical Corp. Strategic Evolution FY’04 – FY’08: Acquire and Define Infection Prevention & Control (IPC) Portfolio FY’09 – FY’10: Substantial Operational and P&L Improvement, while Investing in Sales & Marketing FY’11: Leverage Sales & Marketing and Drive R&D Investments. Close 1-2 Key Acq
Slide 21: Summary
21 Cantel Medical Corp. Summary Growing ~$45B Global Market in Infection Prevention & Control Pure-play focus Fragmented nature creates opportunities for further growth and expansion $393M NYSE Specialty Infection Prevention & Control Leader1 Strong, recession-buffered core business with high future
Slide 22: ( ) Matters™ CROSSTEX
Cantel Medical Corp. (NYSE: CMN) Infection Prevention & Control Matters™ CROSSTEX
Cantel Medical — Investor Presentation (December 2012) on 6ix